PLASMA PHOSPHOLIPID TRANSFER PROTEIN (PLTP) DEFICIENCY REPRESENTS AN ANTI-ATHEROGENIC STATE AND PLTP INHIBITOR HAS ANTI-ATHEROSCLEROSIS ACTION

摘要

This invention provides methods of decreasing apolipoprotein B-containing lipoprotein and of treating atherosclerotic diseases and dyslipidemic diseases by reducing plasma phospholipid transfer protein activity, and methods of identifying chemical compounds for use in such treatments.